Zipalertinib
EGFR Exon 20 Mutation
Cullinan Therapeutics Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the EGFR Exon 20 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Blueprint Medicines Corporation | Phase 1 | CC |
Pebezertinib Blueprint Medicines Corporation | Phase 1 | CC |
Poziotinib M.D. Anderson Cancer Center | Phase 2 | C |
Same molecule, other indications
Zipalertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →